• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

VIVA 17 Round-up: Medtronic touts real-world data for In.Pact Admiral drug-coated balloon

September 12, 2017 By Sarah Faulkner

SurModics touts six-month data for SurVeil DCB

SurmodicsSurModics (NSDQ:SRDX) touted data yesterday at VIVA from the Preveil early feasibility study of its SurVeil drug-coated balloon.

The prospective, single-arm trial was designed to assess the safety and feasibility of the SurVeil DCB in the treatment of patients with symptomatic peripheral artery disease due to de novo lesions of the femoral and popliteal arteries.

The six-month data included results from 13 patients who were treated with the SurVeil DCB. The average lesion length for the group was 56 millimeters.

The study’s clinical measures included primary patency and late lumen loss through six months, plasma paclitaxel levels, resting ankle brachial index/toe brachial index, six-minute walk test and a walking impairment questionnaire at 1, 6, 12, 24 and 36 months.

Key secondary safety endpoints, the team reported, were freedom from major vascular complications, evidence of paclitaxel toxicity or thombolysis in myocardial infarction.

Acute success measures of safety were observed in 100% of the subjects, according to the six-month data. The data also showed primary patency of 100% and mean late lumen loss of 0.27 (+/- 0.54) millimeters at six months.

Median paclitaxel plasma concentration peaked immediately following the procedure, the company said, and was undetectable after 30 days.

“We are encouraged by the early patient data using the Surmodics SurVeil DCB platform and are excited to continue clinical evaluation of the product in the U.S. pivotal trial,” principal investigator Dr. Gary Ansel said in prepared remarks.

“Our goal with the SurVeil DCB is to improve drug transfer and effect on the arterial wall with a lower drug dose and a reduction in the amount of drug reaching tissue outside the area of treatment,” president & CEO Gary Maharaj added. “We are very satisfied with the results of the EFS and believe they are consistent with our encouraging pre-clinical data.”

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: acotecscientific, C.R. Bard, cook medical, Medtronic, Mercator MedSystems, Royal Philips, SurModics Inc.

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS